Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10003)	5/16/1999 12:20:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George, because you have not responded to my Murphy questions, I am going to have to insist you prove you are the same Wohanka. Please provide an exceptional post regarding timely and accurate information provided by Investor Relations at Xoma.

To: aknahow who wrote (10003)	5/16/1999 4:51:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Arch Dermatol 1998 Nov;134(11):1449-54 Off-label dermatologic therapies. Usage, risks, and mechanisms. Li VW, Jaffe MP, Li WW, Haynes HA Department of Medicine, Brigham and Women's Hospital, Boston, Mass., USA. Off-label refers to the prescribing of Food and Drug Administration-approved drugs for a use not indicated on the package insert. The prescribing of off-label drugs may benefit patients with many dermatologic diseases including angiogenesis-related conditions. We surveyed 55 dermatologists from a single large academic program to assess their use of particular drugs for specific skin conditions, their perception of such use as being for Food and Drug Administration-approved or for off-label indications, and their attitudes towards off-label therapies. The practice of prescribing off-label drugs was common among the respondents, many of whom had misperceptions about which conditions are Food and Drug Administration-approved indications and about the legal ramifications of off-label therapies. We suggest that understanding the principles of off-label prescribing in conjunction with the mechanisms of drug action in diseases may help clinicians exercise their judgment in finding innovative therapies for their patients.